IHS will organise a webinar on ‘Assessing Global Healthcare Market Access Risk ‘ on November 7, 2013. The webinar is targeted at pharmaceutical manufacturers, wholesalers and distributors, biotechnology R&D professionals, medical device and equipment manufacturers, healthcare policy makers, regulatory bodies, providers, insurers and facilities, financial institutions and professional services organisations to gain an understanding on conceptual framework of risk assessment, cost/ pricing and market trends pertaining to the healthcare and pharmaceutical sector. The session will provide an overview of the role international reference pricing plays in market access risk.
Discussion points include assessing market access risk, navigating international reference pricing changes and evolution of global drug prices. Gustav Ando, Director, Healthcare and Pharmaceutical Group and Praful Mehta, Senior Healthcare Analyst, IHS are the speakers.
Praful Mehta, Senior Healthcare Analyst, IHS said, “Emerging markets have long been thought as the ultimate elixir to all the troubles of the pharma industry. It is widely believed that Emerging Markets (EM) will contribute to one third of pharma market revenues by 2016. However, they display enormous diversity in terms of overall access to markets and companies cannot rely on one-size-fits-all strategy while navigating these markets. Success in emerging markets will depend on two factors: ability to identify and segregate markets based on market-access risk; and defining and implementing market-tailored strategies for each individual market.”
The webinar link for registration: http://www.ihsapac.com/2013webcast/09-hp-healthcare-pharma/
EP News Bureau